Last update 08 May 2025

Surabgene Lomparvovec

Overview

Basic Info

Drug Type
AAV based gene therapy
Synonyms
+ [1]
Target
Action
inhibitors
Mechanism
VEGF inhibitors(Vascular endothelial growth factor inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet age-related macular degenerationPhase 3
Germany
28 Dec 2021
Wet age-related macular degenerationPhase 3
Hungary
28 Dec 2021
Wet age-related macular degenerationPhase 3
France
28 Dec 2021
Wet age-related macular degenerationPhase 3
United Kingdom
28 Dec 2021
Wet age-related macular degenerationPhase 3
Japan
28 Dec 2021
Wet age-related macular degenerationPhase 3
United States
28 Dec 2021
Wet age-related macular degenerationPhase 3
Puerto Rico
28 Dec 2021
Wet age-related macular degenerationPhase 3
Italy
28 Dec 2021
Wet age-related macular degenerationPhase 3
Spain
28 Dec 2021
Wet Macular DegenerationPhase 3
United States
29 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
106
(cqxftxozoo) = in the study eye were mild or moderate and included conjunctival hemorrhage, increased intraocular pressure, episcleritis, and conjunctival hyperemia. mnwwyuzqwc (fjbmqxaiha )
Positive
16 Jan 2024
Not Applicable
-
rtuaevifpe(baeenxiecj) = three cases of mild intraocular inflammation through 6 months which resolved with topical corticosteroids nupifswnwd (apenlazisc )
-
05 Oct 2023
RGX-314 at an increased dose level of 5 x E11 GC/eye
Not Applicable
-
wjdeznmbxw(zszmvhyppj) = No new drug-related ocular adverse events (AEs) have been reported in Cohorts 1-4 ecsbvlaygv (ysxnjutfbb )
-
05 Oct 2023
Phase 2
60
(kejlawcbpn) = vyjasorlvo cbpbbtagox (xxxundovlr )
Positive
02 Nov 2022
control
(kejlawcbpn) = xpzekorghv cbpbbtagox (xxxundovlr )
Phase 2
20
(hdexywovce) = wsblxoojbi cbnuapspfl (ybzpcbaukp )
Positive
13 Sep 2022
Observational
(hdexywovce) = dmeylrsdlk cbnuapspfl (ybzpcbaukp )
Phase 2
19
(chmoovgblm) = lwbexsktrx ahknhnqcqx (izzeszburl )
Positive
01 Oct 2021
Ranibizumab
(chmoovgblm) = ffugkjlatd ahknhnqcqx (izzeszburl )
Not Applicable
-
(vsatgpmpst) = 20 serious adverse events (SAEs) reported in 13 patients, including one possibly drug-related SAE of significant decrease in vision in Cohort 5 rropbgmrob (ovfiwijsbk )
-
01 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free